‘Alder’ or nothing: biopharma files for $115M IPO
The bulls marched on as Alder Biopharmaceuticals Inc. joined the growing queue of biotechs seeking to prevail on the public markets. The Bothell, Wash.-based company filed a registration statement with the SEC seeking to raise up to $115 million in its initial public offering (IPO) to fund its ongoing clinical program for lead compound ALD403, a monoclonal antibody targeting calcitonin gene-related peptide, or CGRP, to prevent migraine headache. Filing as an emerging growth company, Alder plans to list on the Nasdaq Global Market under the ticker ALDR.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST